Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "THA"

8488 News Found

Northamptonshire NHS Trust ditches disposable cups in bold sustainability move
Packaging | March 27, 2026

Northamptonshire NHS Trust ditches disposable cups in bold sustainability move

The Trust’s shift from single-use compostable cups to a reusable system was driven by the need to reduce environmental impact and control long-term costs


Sea Urchin spines inspire breakthrough sensor that detects water flow instantly
R&D | March 06, 2026

Sea Urchin spines inspire breakthrough sensor that detects water flow instantly

Their findings, published in the journal Nature, reveal that the spines’ unique porous internal structure allows them to convert water movement into measurable electrical signals


BMS reports positive Phase 2 data for Luspatercept in alpha-thalassemia
Clinical Trials | February 23, 2026

BMS reports positive Phase 2 data for Luspatercept in alpha-thalassemia

Both non-transfusion-dependent and transfusion dependent cohorts met their respective primary and secondary endpoints


Axol Bioscience acquires ophthalmology business from Newcells Biotech
News | February 19, 2026

Axol Bioscience acquires ophthalmology business from Newcells Biotech

Acquisition expands Axol’s portfolio of iPSC-derived retinal organoid and retinal pigment epithelium (RPE) models


Manthan 2026 wraps up, spotlighting India’s life sciences & clinical research future
News | January 20, 2026

Manthan 2026 wraps up, spotlighting India’s life sciences & clinical research future

India in the Changing Landscape of Life-Sciences Research & Development


FDA okays AQVESME as first treatment for anemia in alpha- & beta-thalassemia
News | December 27, 2025

FDA okays AQVESME as first treatment for anemia in alpha- & beta-thalassemia

The approval makes AQVESME the only FDA-approved therapy for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia


Alembic announces USFDA final approval for Travoprost Ophthalmic Solution USP, 0.004%
Drug Approval | December 20, 2025

Alembic announces USFDA final approval for Travoprost Ophthalmic Solution USP, 0.004%

Travoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension


Alembic receives USFDA final approval for Loteprednol Etabonate and Tobramycin Ophthalmic suspension
News | December 12, 2025

Alembic receives USFDA final approval for Loteprednol Etabonate and Tobramycin Ophthalmic suspension

The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Zylet Ophthalmic Suspension, 0.5%/0.3%, of Bausch & Lomb